|
A total of about 60,000 volunteers have been given Chinese COVID-19
vaccines as part of phase-3 clinical trials, with no severe side-effects
reported, a Chinese official said Tuesday. Four
Chinese vaccine candidates have entered international phase-3 clinical
trials so far, said Tian Baoguo with the Ministry of Science and
Technology at a news conference in Beijing. All trials are progressing
well, he said, with initial indications that the vaccines are safe. According
to Tian, the most common adverse reactions in phase-3 clinical trials
are pain and swelling at the injection site, followed by fever, both of
which are mild. The
two inactivated vaccines developed by China National Biotec Group
(CNBG), which is affiliated to Sinopharm, and the Wuhan Institute of
Biological Products, have started phase-3 clinical trials in 10
countries, with more than 50,000 volunteers taking part, said Liu
Jingzhen, chairman of Sinopharm. Sinovac
Biotech, another vaccine developer, said that the company's partners in
Brazil, Indonesia and Turkey have established monitoring systems for
adverse reactions in accordance with internationally accepted standards.
So far, no severe adverse reactions related to COVID-19 vaccines have
been reported.
|
Related News
